press releases
January 21, 2022
Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma

August 2, 2021
Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments

April 27, 2021
Arch Oncology Secures $105 Million Series C Financing

April 10, 2021
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021

April 7, 2021
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO

March 10, 2021
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021

February 16, 2021
Arch Oncology to Participate in Upcoming Conferences

February 9, 2021
Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors

January 6, 2021
Arch Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference

December 7, 2020
Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma

December 6, 2020
Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020

November 16, 2020
Arch Oncology Appoints Ronald Krasnow, Esq. as Chief Operating Officer

November 9, 2020
Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020

October 26, 2020
Arch Oncology to Present at Upcoming Conferences

October 5, 2020
Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors

June 22, 2020
Arch Oncology Announces Formation of Scientific Advisory Board

April 21, 2020
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors

August 12, 2019
Arch Oncology Appoints Drew Dennison to Board of Directors

May 22, 2019
Arch Oncology Appoints Kirk Christoffersen as Chief Business Officer

March 29, 2019
Arch Oncology to Present Preclinical Data on Highly-differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019

March 25, 2019
Arch Oncology Raises $50 Million Series B Financing

February 6, 2019
Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-class Profile